Skip to main content
OpenTrials
Completed

NCT Number: NCT03507205

Korean Nationwide Multicenter Pooled Registry of Drug-Eluting Stents

The objective of this study is to evaluate the long-term efficacy and safety of coronary stenting with the various types of drug-eluting stents (DES) and to determine clinical device and procedural success during commercial use of DES in the real world.

The investigators will compare EES (Xience V/Promus and Xience Prime), SES (Cypher), ZES (Resolute Integrity, Endeavor Resolute, Endeavor), and BES (Biomatrix, Biomatrix Flex, and Nobori).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Coronary Artery Disease Arterial Occlusive Diseases Arteriosclerosis Cardiovascular Diseases Coronary Disease Heart Diseases Myocardial Ischemia Vascular Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Wonju Severance Christian Hospital, Wŏnju, Gangwon-do, South Korea

Loading trial locations.

About this study

The Grand Drug-Eluting Stent (Grand-DES) Registry incorporated five different multicenter registries in South Korea. The EXCELLENT prospective cohort and the EXCELLENT-PRIME registry were dedicated for durable polymer-coated everolimus-eluting stents (DP-EES; Xience V/Promus and Xience Prime) or 1st-generation sirolimus-eluting stents (Cypher), the HOST-RESOLINTE and RESOLUTE-Korea registry for durable polymer-coated zotarolimus-eluting stents (DP-ZES; Resolute Integrity and Endeavor Resolute) or 1st-generation Endeavor-ZES, and the HOST-BIOLIMUS-3000-Korea registry for biodegradable polymer-coated biolimus-eluting stents (BP-BES; Biomatrix, Biomatrix Flex, and Nobori). During the period of 2008 through 2014, all registries enrolled all-comers without any exclusion criteria except patient's withdrawal of consent.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The patient agrees to participate in this study by signing the informed consent form.
  • Alternatively, a legally authorized patient representative may agree to the patient's participation in this study and sign the informed consent form.

Exclusion criteria

  • There are no exclusion criteria for this registry.

Treatment and study plan

Biomatrix; Biomatrix Flex; Nobori

Device

Biodegradable polymer-coated biolimus-eluting stents

Other names: BP-BES

Xience Prime

Device

Durable polymer-coated everolimus-eluting stents

Other names: DP-EES-Prime

Xience V/Promus; Cypher

Device

Durable polymer-coated everolimus-eluting stents; Sirolimus-eluting stents

Other names: DP-EES; SES

DP-ZES-RI

Device

Durable polymer-coated zotarolimus-eluting stents

Other names: Resolute Integrity

Endeavor; Resolute

Device

Durable polymer-coated zotarolimus-eluting stents

Other names: DP-ZES

Primary outcomes

  1. Target lesion failure

    Time frame: 36 months

    A composite of cardiac death, target-vessel myocardial infarction, and clinically-driven target lesion revascularization

Secondary outcomes

  1. Patient-oriented composite outcome

    Time frame: 36 months

    A composite of all-cause death, all-cause myocardial infarction, and any repeat revascularization

  2. All-cause death

    Time frame: 36 months

    All-cause death

  3. Cardiac death

    Time frame: 36 months

    Cardiac death

  4. All-cause myocardial infarction

    Time frame: 36 months

    All-cause myocardial infarction

  5. Target-vessel myocardial infarction

    Time frame: 36 months

    Target-vessel myocardial infarction

  6. Any repeat revascularization

    Time frame: 36 months

    Any repeat revascularization

  7. Clinically-driven target vessel revascularization

    Time frame: 36 months

    Clinically-driven target vessel revascularization

  8. Clinically-driven target lesion revascularization

    Time frame: 36 months

    Clinically-driven target lesion revascularization

  9. Definite or probable stent thrombosis

    Time frame: 36 months

    Definite or probable stent thrombosis

Sponsors and collaborators

Lead sponsor

Seoul National University Hospital

Other

Registry information

Acronym: Grand-DES

Important dates

Study start
2008
Primary completion
2017
Study completion
2017
First posted
Apr 24, 2018
Registry last updated
Apr 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.